Nucresiran for Transthyretin Amyloidosis Polyneuropathy
(TRITON-PN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the effectiveness of nucresiran for individuals with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a condition that affects nerves and can impact movement and quality of life. Researchers seek to determine if nucresiran improves symptoms such as nerve damage and walking speed and if it is more effective at lowering a specific protein in the blood compared to another treatment, vutrisiran. Participants will either receive nucresiran directly or start with vutrisiran before switching to nucresiran. Suitable candidates have a diagnosis of hATTR-PN and experience nerve-related issues from this condition. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Earlier studies found that patients using vutrisiran, a medicine for transthyretin amyloidosis, tolerated it well and found it safe even after nearly five years. Although direct safety data for nucresiran is not yet available, its similarity to existing treatments suggests it might also be well-tolerated. However, since nucresiran remains under testing and lacks approval from health authorities, researchers continue to closely study its safety. So far, similar treatments have not reported any serious safety issues.12345
Why do researchers think this study treatment might be promising for polyneuropathy?
Researchers are excited about nucresiran for treating transthyretin amyloidosis polyneuropathy because it offers a novel approach to managing this condition. Unlike most treatments that require frequent administration, nucresiran is administered just twice a year, which could significantly improve patient convenience and adherence. Additionally, nucresiran works by silencing the gene responsible for the abnormal protein production, potentially offering a more direct and effective method of addressing the disease's root cause compared to existing treatments. This innovative mechanism has the potential to halt or even reverse the progression of nerve damage associated with the condition.
What evidence suggests that this trial's treatments could be effective for transthyretin amyloidosis polyneuropathy?
Research shows that nucresiran, which participants in this trial may receive, can significantly lower the amount of transthyretin (TTR) in the blood. High TTR levels are linked to hereditary transthyretin amyloidosis polyneuropathy (hATTR-PN), a condition affecting the nerves. In earlier studies, patients experienced a 90.3% drop in TTR levels just 15 days after a single dose of nucresiran. By day 29, the reduction increased to 96.5%, suggesting that the treatment might help slow the disease. Nucresiran reduces TTR production, potentially lessening nerve damage caused by the condition. Early findings suggest that nucresiran could improve symptoms and enhance the quality of life for people with hATTR-PN.16789
Who Is on the Research Team?
Medical Director
Principal Investigator
Alnylam Pharmaceuticals Inc
Are You a Good Fit for This Trial?
This trial is for patients with hereditary transthyretin amyloidosis who have polyneuropathy. They must have a specific TTR gene variant, a certain level of nerve impairment, and be able to perform daily activities at least 60% as well as a healthy person.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either nucresiran 300 mg SC every 6 months or vutrisiran 25 mg SC every 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Extension
Participants may continue receiving nucresiran 300 mg SC every 6 months
What Are the Treatments Tested in This Trial?
Interventions
- Nucresiran
Trial Overview
The study tests Nucresiran's effectiveness on nerve damage, quality of life, nutrition, disability, and walking speed in hATTR-PN patients. It aims to show that Nucresiran is better than Vutrisiran at reducing serum TTR levels.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period
Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alnylam Pharmaceuticals
Lead Sponsor
Dr. Yvonne Greenstreet
Alnylam Pharmaceuticals
Chief Executive Officer since 2021
MD from the University of Leeds, MBA from INSEAD
Dr. Pushkal Garg
Alnylam Pharmaceuticals
Chief Medical Officer since 2016
MD from Columbia University
Citations
TRITON-PN: A Study to Evaluate the Efficacy and Safety of ...
The purpose of this study is to: Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, ...
Alnylam Pharmaceuticals Press Release | May 12, 2025
The Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress.
Transthyretin Amyloid Cardiomyopathy: The Plot Thickens ...
The phase I trial of six participants supported the safety and plausibility of this therapy, demonstrating a mean 52% reduction in serum TTR ...
4.
amyloidosisnewstoday.com
amyloidosisnewstoday.com/news/new-study-tests-nucresirans-potential-slow-nerve-damage/New study tests nucresiran's potential to slow nerve damage
By reducing TTR protein production, nucresiran is expected to slow disease progression in FAP and other forms of ATTR amyloidosis, hereditary or ...
5.
alnylampharmaceuticalsinc.gcs-web.com
alnylampharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/alnylam-announces-interim-phase-1-data-nucresiran-aln-ttrsc04Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN ...
In subjects receiving a single 300 mg dose of nucresiran, mean serum TTR reduction of 90.3% was observed at Day 15, 96.5% at Day 29, and 92.6% ...
Nov 17, 2024 Press Release for Alnylam
The safety and efficacy of nucresiran have not been established or evaluated by the FDA, EMA or any other health authority. About ATTR.
Efficacy and safety of patisiran for ATTRv-PN: a systematic ...
Patisiran is a small interfering RNA (siRNA), offering potential as a genetic-level therapy for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv ...
Realizing the therapeutic potential of rapid knockdown ...
Transthyretin amyloidosis (ATTR) is a progressive, debilitating, and fatal disease caused by ongoing accumulation of toxic transthyretin (TTR) ...
9.
rarediseaseadvisor.com
rarediseaseadvisor.com/news/long-term-vutrisiran-appears-safe-well-tolerated-attr/Long-Term Vutrisiran Appears Safe and Well-Tolerated in ...
Vutrisiran is well-tolerated and has an acceptable safety profile in patients with ATTR who are treated with it for up to 58 months.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.